Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes

BIOLOGICAL2 trials

Sponsors

City of Hope Medical Center

Conditions

B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin LymphomaB-Cell Prolymphocytic LeukemiaHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedPost-Transplant Lymphoproliferative DisorderRecurrent Adult Burkitt LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular Lymphoma

Phase 1

Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma

Active, not recruitingNCT02051257

City of Hope Medical CenterRecurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma +2

Start: 2014-06-19End: 2027-03-02Target: 51Updated: 2026-03-31

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

Active, not recruitingNCT02153580

City of Hope Medical CenterB-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia, High Grade B-Cell Lymphoma, Not Otherwise Specified +10

Start: 2014-09-24End: 2026-09-02Updated: 2025-10-06

Related Papers

Results from a Phase 1 Study to Evaluate a Memory-Enriched CD19-Specific CAR T Cell Platform in Adult Patients with CD19+ B-Cell Non-Hodgkin Lymphoma (B-NHL)

Blood2021-11-051 citations

CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma

Blood Advances2021-09-07111 citations

CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma

Blood2019-11-1312 citations